Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.
暂无分享,去创建一个
R. C. Layton | N. Petrovsky | A. Gigliotti | P. Gao | K. Harrod | F. Koster | J. Knight | Nathaniel Donart | J. Pyles | Zemmie Pollock | Jennifer B. Knight | Peng Gao | Kevin S. Harrod | Andrew P. Gigliotti
[1] R. C. Layton,et al. Enhanced Immunogenicity, Mortality Protection, and Reduced Viral Brain Invasion by Alum Adjuvant with an H5N1 Split-Virion Vaccine in the Ferret , 2011, PloS one.
[2] N. Petrovsky,et al. Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. , 2011, Glycobiology.
[3] Shinji Watanabe,et al. Subclinical Brain Injury Caused by H5N1 Influenza Virus Infection , 2011, Journal of Virology.
[4] N. Petrovsky,et al. Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations , 2011, The Journal of general virology.
[5] C. Feare,et al. Persistence of Highly Pathogenic Avian Influenza Viruses in Natural Ecosystems , 2010, Emerging infectious diseases.
[6] N. Petrovsky,et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses , 2010, The Journal of general virology.
[7] Alan S. Perelson,et al. Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.
[8] W. Keitel,et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. , 2010, Vaccine.
[9] K. Hoschler,et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.
[10] W. Keitel,et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. , 2009, Vaccine.
[11] R. Webster,et al. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. , 2009, Vaccine.
[12] I. Barr,et al. Evaluation of Vaccines for H5N1 Influenza Virus in Ferrets Reveals the Potential for Protective Single-Shot Immunization , 2009, Journal of Virology.
[13] R. C. Layton,et al. Ferret model of avian influenza demonstrates dose and strain dependant pathology and viral load in brain , 2009 .
[14] W. Keitel,et al. Adjuvants for pandemic influenza vaccines. , 2009, Current topics in microbiology and immunology.
[15] R. Tripp,et al. Animal models for evaluation of influenza vaccines. , 2009, Current topics in microbiology and immunology.
[16] T. Tumpey,et al. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. , 2009, Advances in virus research.
[17] T. Chotpitayasunondh,et al. Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children , 2008, PloS one.
[18] J. McVernon,et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. , 2008, Vaccine.
[19] B. Palache. New vaccine approaches for seasonal and pandemic influenza. , 2008, Vaccine.
[20] W. Keitel,et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. , 2008, The Journal of infectious diseases.
[21] M. Saville,et al. Improving seasonal and pandemic influenza vaccines , 2008, Influenza and other respiratory viruses.
[22] G. Kayali,et al. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[23] R. Tripp,et al. Recombinant vaccines for influenza virus. , 2008, Current opinion in investigational drugs.
[24] D. Bernstein,et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. , 2008, The Journal of infectious diseases.
[25] J. Treanor,et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. , 2008, The Journal of infectious diseases.
[26] N. Petrovsky. Freeing vaccine adjuvants from dangerous immunological dogma , 2008, Expert review of vaccines.
[27] A. Osterhaus,et al. Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.
[28] A. Osterhaus,et al. Vaccination of Macaques with Adjuvanted Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge without Disease Enhancement , 2007, Journal of Virology.
[29] D. Krewski,et al. Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide , 2007, Journal of toxicology and environmental health. Part B, Critical reviews.
[30] G. Leroux-Roels,et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.
[31] Steven Riley,et al. Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate , 2007, PLoS medicine.
[32] K. Subbarao,et al. Scientific barriers to developing vaccines against avian influenza viruses , 2007, Nature Reviews Immunology.
[33] J. Katz,et al. Influenza: Propagation, Quantification, and Storage , 2006, Current protocols in microbiology.
[34] R. Webster,et al. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. , 2006, The Journal of infectious diseases.
[35] N. Cox,et al. Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model , 2006, Proceedings of the National Academy of Sciences.
[36] A. Hampson. Ferrets and the challenges of H5N1 vaccine formulation. , 2006, The Journal of infectious diseases.
[37] R. Webster,et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. , 2006, The Journal of infectious diseases.
[38] M. Zambon,et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.
[39] N. Petrovsky. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. , 2006, Vaccine.
[40] Mark Wolff,et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.
[41] M. Kieny,et al. Development and evaluation of influenza pandemic vaccines , 2006, The Lancet Infectious Diseases.
[42] R. Webster,et al. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] Diego G. Silva,et al. Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses , 2004, Immunology and cell biology.
[44] John A. Maher,et al. The Ferret: An Animal Model to Study Influenza Virus , 2004, Lab Animal.
[45] R. Webster,et al. Protection and compensation in the influenza virus-specific CD8+ T cell response , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Zambon,et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.
[47] W. Gerhard. The role of the antibody response in influenza virus infection. , 2001, Current topics in microbiology and immunology.
[48] Keiji Fukuda,et al. Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.
[49] P. Cooper,et al. The adjuvanticity of gamma inulin , 1988, Immunology and cell biology.
[50] A. Kendal,et al. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection , 1988, Journal of clinical microbiology.